Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women
Author:
Affiliation:
1. London School of Hygiene and Tropical Medicine; London UK
2. Cancer Research UK and UCL Cancer Trials Centre; London UK
3. Clinical Trials and Statistics Unit; The Institute of Cancer Research; Sutton UK
Publisher
Wiley
Subject
Pharmacology (medical)
Link
http://onlinelibrary.wiley.com/wol1/doi/10.1002/14651858.CD003370.pub3/fullpdf
Reference113 articles.
1. Randomized trial of tamoxifen versus aminoglutethimide and versus combined tamoxifen and aminoglutethimide in advanced postmenopausal breast cancer;Alonso-Munzo;Oncology,1988
2. Fadrozole versus megestrol acetate: a double-blind randomised trial in advanced breast cancer;Bezwoda;Oncology,1998
3. Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma;Bonneterre;Cancer,2001
4. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the tamoxifen or arimidex randomized group efficacy and tolerability study;Bonneterre;Journal of Clinical Oncology,2000
5. Anastrozole (Arimidex) versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: survival analysis and updated safety results;Nabholtz;European Journal of Cancer,2003
Cited by 68 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Impact of Motivational Interviewing on Psychosocial and Symptom Outcomes During Breast Cancer Endocrine Therapy;2024-09-03
2. A randomized controlled trial of hypnosis to manage musculoskeletal pain in breast cancer survivors taking aromatase inhibitors.;Psychology of Consciousness: Theory, Research, and Practice;2024-02-08
3. A Case Report of Advanced Male Breast Cancer with Lung Metastasis Treated with Endocrine Therapy Combined with Palbociclib;Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association);2024
4. Metastatic ER+ Breast Cancer: Mechanisms of Resistance and Future Therapeutic Approaches;International Journal of Molecular Sciences;2023-11-11
5. Tailoring Potential Natural Compounds for the Treatment of Luminal Breast Cancer;Pharmaceuticals;2023-10-16
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3